Related Experiment Video
Updated: Jul 26, 2026
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors
Paolo Romania1, Loredana Cifaldi1,2, Paula Gragera1
1Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Introduction:
Natural Killer (NK) cells play a key role in both innate and adaptive immune responses against viruses and tumor cells. Their function relies on the dynamic balance between activating and inhibitory signals, which are mediated by receptors that bind ligands expressed on target cells. While much is known about the function and expression patterns of NK cell activating receptors (NKARs), many of their ligands remain unidentified.
Methods:
K562 cells were transduced with a shRNA library targeting 15,000 genes and co-cultured with NK cells from healthy donors. Surviving clones were tested in cytotoxicity and degranulation assays. PLAC1 was cloned from JEG3 cells in a lentiviral vector and transfected in K562 cells. PLAC1-related gene expression and survival data were obtained from the TCGA database and analyzed using R. PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.
Results:
We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. The most promising candidates were functionally validated through single-target gene silencing and overexpression. Among them, the placenta-specific 1 (PLAC1) gene stood out, as its inhibition conferred the greatest protection to target cells from NK cell lysis, while overexpression of PLAC1 significantly increased NK cell degranulation. Importantly, PLAC1 was found to interact with NKAR fusion proteins, including NKG2D, DNAM1 NKp44 and NKp30, suggesting its potential involvement in NK cell function. PLAC1 is typically silent in normal tissues, with the exception of placental trophoblasts and testicular germ cells, but is markedly overexpressed in a wide range of tumors. Notably, its prognostic significance appears to be tumor-type specific, associating with either favorable or poor outcomes depending on the cancer context.
Discussion:
Our study identifies PLAC1 as a novel potential ligand for NKARs, suggesting it could be a valuable target for pharmacological strategies aimed at enhancing NK cell recognition. This finding holds promise for improving the efficacy of NK cell-based immunotherapies and advancing their clinical application.
Insights
Researchers identified placenta-specific 1 (PLAC1) as a novel ligand for Natural Killer cell activating receptors (NKARs). This discovery may enhance NK cell-based immunotherapies by targeting PLAC1 to improve cancer treatment outcomes.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Natural Killer (NK) cells are crucial for immune responses against viral infections and tumors.
- NK cell activity is regulated by a balance of activating and inhibitory signals mediated by receptors and their ligands.
- Many ligands for NK cell activating receptors (NKARs) remain unidentified, limiting therapeutic strategies.
Purpose of the Study:
- To identify novel ligands for NKARs involved in NK cell-mediated cytotoxicity.
- To investigate the role of the placenta-specific 1 (PLAC1) gene in NK cell function and cancer.
- To explore the potential of PLAC1 as a therapeutic target for enhancing NK cell-based immunotherapies.
Main Methods:
- A genome-wide shRNA screen was performed using K562 cells and primary NK cells to identify genes affecting NK cell cytotoxicity.
- Functional validation of candidate genes, including PLAC1, was conducted through gene silencing and overexpression studies.
- Interactions between PLAC1 and NKARs were assessed using fusion protein assays; gene expression data were analyzed from TCGA and HPA databases.
Main Results:
- Downregulation of ten candidate genes, particularly PLAC1, significantly protected target cells from NK cell lysis.
- Overexpression of PLAC1 enhanced NK cell degranulation and demonstrated interaction with multiple NKARs (NKG2D, DNAM1, NKp44, NKp30).
- PLAC1 is normally silenced in most tissues but overexpressed in various tumors, with prognostic significance varying by cancer type.
Conclusions:
- Placenta-specific 1 (PLAC1) is identified as a novel potential ligand for NKARs.
- PLAC1 represents a promising target for developing strategies to augment NK cell recognition and improve immunotherapies.
- Targeting PLAC1 could enhance the efficacy of NK cell-based treatments for various cancers.
Related Concept Videos
01:25Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...